Atopic Dermatitis Treatment Guide: Stepwise Therapy from Topicals to Biologics

Effective atopic dermatitis (AD) management demands a structured, stepwise approach tailored to severity, phenotype, and patient factors. This guide synthesizes current guidelines (AAD, EADV, NICE) into an actionable framework.

Step 0: Universal Foundation (All Severities)

• Moisturize 2–3×/day: Ceramide-containing, fragrance-free, petrolatum-rich. Apply to damp skin post-bath.
• Gentle bathing: Lukewarm, ≤10 min, non-soap cleanser, pat dry, apply medications + moisturizer within 3 minutes.
• Trigger management: Diary → avoidance (irritants, allergens, heat, stress).
• Clothing: Cotton, silk, bamboo; avoid wool, synthetics, tags.
• Nail care: Short, smooth.
• Humidifier: 40–50% in bedroom (winter).

Step 1: Mild AD (IGA 1–2, Limited BSA)

• Proactive topical therapy: Low-potency TCS (hydrocortisone 2.5%, desonide 0.05%) or TCI (tacrolimus 0.03%, pimecrolimus 1%) 2×/week on prior flare sites ("weekend therapy").
• Crisaborole 2% ointment (PDE4 inhibitor): Non-steroidal, face/fold-safe, BID.
• Topical JAK inhibitor (ruxolitinib 1.5%): ≥12 years, limited BSA.

Step 2: Moderate AD (IGA 3, BSA 10–30%)

• Mid-potency TCS: Triamcinolone 0.1%, fluocinolone 0.025% — 2×/day × 2 weeks → taper to proactive 2×/week.
• TCI (tacrolimus 0.1%): Face/folds, maintenance.
• Narrowband UVB phototherapy: 2–3×/week × 8–12 weeks (if widespread).
• Consider systemic therapy if: Topical failure, significant QoL impact, frequent flares.

Step 3: Severe AD (IGA 4, BSA >30% or High-Impact)

• Short-course potent TCS: Clobetasol 0.05% (body) / betamethasone 0.05% (scalp) 1–2×/day × 1–2 weeks → bridge to systemic.
• Systemic therapy — Biologics preferred (per guidelines):
  • Dupilumab (anti-IL-4Rα): ≥6 months (US) / ≥12 years (EU). q2 weeks (adults), weight-based (pediatrics). First-line biologic.
  • Tralokinumab (anti-IL-13): ≥12 years. q2 weeks → q4 weeks. Less conjunctivitis.
  • JAK inhibitors (oral): Upadacitinib (15/30 mg daily ≥12 years), Abrocitinib (100/200 mg daily ≥18 years). Rapid itch relief. Boxed warnings (infection, thrombosis, malignancy, lipids).
• Traditional immunosuppressants (bridge/access): Cyclosporine (rapid, short-term), methotrexate, azathioprine, MMF — require intensive monitoring.

Special Situations

• Face/eyelids/genitals: TCI, crisaborole, low-potency TCS (≤2 weeks), ruxolitinib.
• Hand eczema: Potent TCS + barrier gloves + irritant avoidance; consider alitretinoin (if available) or systemic therapy.
• Pediatric: Weight-based dosing, growth monitoring, minimize potent TCS duration.
• Pregnancy/lactation: TCS (low-mid potency preferred), TCI (limited data), phototherapy, dupilumab (pregnancy registry favorable). Avoid JAK inhibitors, traditional immunosuppressants.

Monitoring & Assessment

• Validated tools: EASI, SCORAD, IGA, POEM (patient-oriented), DLQI/CDLQI.
• Frequency: q2–4 weeks during optimization; q3–6 months maintenance.
• Labs per agent: CBC, LFTs, lipids, renal, TB, eosinophils, CPK (JAK inhibitors).

Adherence Optimization

• Written action plan (flare vs. maintenance).
• Fingertip unit (FTU) teaching.
• Simplify regimens; align with daily routine.
• Address steroid phobia (education on risks of undertreatment).
• Digital tools: apps for tracking, reminders, telehealth check-ins.

AD treatment has entered a transformative era. Matching the right therapy to the right patient at the right time—supported by education and shared decision-making—enables disease control previously unimaginable.